News | July 29, 2024
Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
ProtocolCopilot leverages advanced artificial intelligence to streamline the process of understanding and adhering to clinical research protocols
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Subscribe To Our Newsletter & Stay Updated
